Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $101
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Buy rating on Edwards Lifesciences (NYSE:EW) and raises the price target from $97 to $101.
May 18, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Edwards Lifesciences and raises the price target from $97 to $101.
The news of Truist Securities maintaining a Buy rating and raising the price target for Edwards Lifesciences (NYSE:EW) from $97 to $101 indicates a positive outlook for the company's stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100